Upstream Bio (UPB) Stock Overview
A clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
UPB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Upstream Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.72 |
| 52 Week High | US$33.68 |
| 52 Week Low | US$5.14 |
| Beta | 0 |
| 1 Month Change | 26.89% |
| 3 Month Change | -62.43% |
| 1 Year Change | 52.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.82% |
Recent News & Updates
Recent updates
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data
Feb 12Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans
Jul 27
Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent
Apr 17We Think Upstream Bio (NASDAQ:UPB) Can Afford To Drive Business Growth
Apr 12Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation
Dec 16Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry
Dec 07Shareholder Returns
| UPB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.7% | 5.0% | 3.5% |
| 1Y | 52.8% | 40.3% | 31.0% |
Return vs Industry: UPB exceeded the US Biotechs industry which returned 40.3% over the past year.
Return vs Market: UPB exceeded the US Market which returned 31% over the past year.
Price Volatility
| UPB volatility | |
|---|---|
| UPB Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: UPB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: UPB's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 75 | E. Sutherland | upstreambio.com |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Upstream Bio, Inc. Fundamentals Summary
| UPB fundamental statistics | |
|---|---|
| Market cap | US$516.99m |
| Earnings (TTM) | -US$143.44m |
| Revenue (TTM) | US$2.85m |
Is UPB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UPB income statement (TTM) | |
|---|---|
| Revenue | US$2.85m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.85m |
| Other Expenses | US$146.30m |
| Earnings | -US$143.44m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,026.03% |
| Debt/Equity Ratio | 0% |
How did UPB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/06 02:23 |
| End of Day Share Price | 2026/04/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Upstream Bio, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cory Kasimov | Evercore ISI |
| Tessa Romero | J.P. Morgan |
| Joseph Catanzaro | Mizuho Securities USA LLC |